Zeneca

British multinational pharmaceutical company

Zeneca Group PLC

Company type| Public limited company
Industry| Pharmaceutical
Founded| 1993
Defunct| 1999; 26 years ago (1999)
Fate| Merged with Astra AB
Successor| AstraZeneca
Headquarters| London, UK
Products| Pharmaceutical products

Zeneca (officially Zeneca Group PLC) was a British multinational pharmaceutical company headquartered in London, United Kingdom. It was formed in June 1993 by the demerger of the pharmaceuticals and agrochemicals businesses of Imperial Chemical Industries into a separate company listed on the London Stock Exchange.[1]

In 1999, Zeneca and the Sweden-based pharmaceutical company Astra AB merged to form AstraZeneca plc.[2][3]

Zeneca's largest therapeutic area was oncology, in which its key products included Casodex, Nolvadex and Zoladex.[4] Other key products included heart drug Tenormin.[5]

## Name

[edit]

"Zeneca" was an invented name created by the branding consultancy Interbrand.[6] Interbrand had been instructed to find a name which began with a letter from either the top or bottom of the alphabet and was phonetically memorable, of no more than three syllables and did not have an offensive meaning in any language.[6]

## History

[edit]

In December 1994, Zeneca agreed the acquisition of 50% of Salick Health Care, an operator of cancer care centres in the United States, in a transaction which valued Salick at US$440 million.[7] Zeneca announced the sale of its textile colours business to the German group BASF in May 1996.[8] Zeneca announced it would purchase the remaining 50% of Salick Health Care that it did not already own on 28 March 28, 1997.[9] In December 1997, Zeneca acquired the US fungicide operations of Ishihara Sangyo Kaisha, along with the international distribution rights to four recently developed fungicides, herbicides and pest control products, for US$500 million.[10][11]

In May 1998, Zeneca announced that Tom McKillop, then the head of its drugs division, would succeed Sir David Barnes as chief executive, with Barnes becoming non-executive chairman of the company.[12] In November 1998, Zeneca announced that it would sell its Zeneca Specialties division, including its biocides, industrial colours, life science molecules, performance and intermediate chemicals and resins activities.[13] On 11 December 1998, Zeneca and Astra AB announced a £48 billion merger.[14] In February 1999, it was reported that Zeneca would sue the US Food and Drug Administration over its decision to allow Gensia Sicor to produce a generic version of its anaesthetic Diprivan.[15] The merger between Zeneca and Astra AB was completed in April 1999, forming AstraZeneca plc.[16]

## See also

[edit]

* London portal
* Companies portal

* Pharmaceutical industry in the United Kingdom

## References

[edit]

1. ^ "Timetable for Zeneca demerger spelled out". The Independent. 26 February 1993. Archived from the original on 7 May 2022. Retrieved 5 July 2011.
2. ^ "Zeneca and Astra merge to form drug giant". BBC News. 9 December 1998. Retrieved 5 July 2011.
3. ^ "Corporate Profile: The arranged marriage". The Independent. 24 February 1999. Archived from the original on 7 May 2022. Retrieved 5 July 2011.
4. ^ "Pound batters drug giant". BBC News. 6 August 1998. Retrieved 5 July 2011.
5. ^ "Zeneca profits up 42% in first year after demerger: Volume and price growth, but conditions remain tough". The Independent. 4 March 1994. Archived from the original on 7 May 2022. Retrieved 5 July 2011.
6. ^ a b "The name game". The Telegraph. 14 January 2001. Retrieved 25 May 2012.
7. ^ "Zeneca to Extend Its Reach into Cancer Care Services". The New York Times. 23 December 1994. Retrieved 5 July 2011.
8. ^ "Zeneca sells loss-making dye business for pounds 150m". The Independent. 9 May 1996. Archived from the original on 7 May 2022. Retrieved 5 July 2011.
9. ^ "Zeneca to Buy Rest of Salick Health Care". The New York Times. 28 March 1997. Retrieved 6 July 2011.
10. ^ "Zeneca buys pounds 300m fungicide business from Japanese rival". The Independent. 18 December 1997. Archived from the original on 7 May 2022. Retrieved 5 July 2011.
11. ^ "Zeneca Group Buys U.S. Fungicide Business". The New York Times. 18 December 1997. Retrieved 5 July 2011.
12. ^ "Drugs chief appointed new head of Zeneca". The Independent. 23 May 1998. Archived from the original on 7 May 2022. Retrieved 5 July 2011.
13. ^ "Zeneca mulls specialities sale". BBC News. 12 November 1998. Retrieved 5 July 2011.
14. ^ "Has Zeneca chosen wisely?". The Independent. 11 December 1998. Archived from the original on 7 May 2022. Retrieved 5 July 2011.
15. ^ "Zeneca to sue US drug monitor". The Independent. 9 February 1999. Archived from the original on 7 May 2022. Retrieved 5 July 2011.
16. ^ "The Lowdown: McKillop gives his opponents the treatment". The Independent. 21 September 2003. Retrieved 5 July 2011.[dead link‍]

* v
* t
* e

AstraZeneca

Products|

* Acalabrutinib
* Anastrozole
* Andexanet alfa
* Anifrolumab
* Asfotase alfa
* Atenolol
* Benralizumab
* Bicalutamide
* Brompheniramine
* Budesonide
* Budesonide/formoterol
* Budesonide/glycopyrronium bromide/formoterol
* Candesartan
* Dapagliflozin
* Disufenton sodium
* Durvalumab
* Eculizumab
* Esomeprazole
* Exenatide
* FluMist
* Fulvestrant
* Gefitinib
* Glycopyrronium bromide/formoterol
* Goserelin
* Isosorbide mononitrate
* Metoprolol
* Motavizumab
* Olaparib
* Omeprazole
* Osimertinib
* Palivizumab
* Propofol
* Quetiapine
* Ravulizumab
* Roflumilast
* Rosuvastatin
* Roxadustat
* Salbutamol/budesonide
* Savolitinib
* Saxagliptin
* Sebelipase alfa
* Selumetinib
* Sodium zirconium cyclosilicate
* Tamoxifen
* Ticagrelor
* Tixagevimab/cilgavimab
* Trastuzumab deruxtecan
* Vandetanib
* Vaxzevria
* Ximelagatran
* Zafirlukast
* Zolmitriptan

Predecessors and
acquired companies|

* Astra AB
* Alexion Pharmaceuticals
* Cambridge Antibody Technology
* MedImmune
* Zeneca

People|

* Tom McKillop
* Louis Schweitzer

* Category
* Commons

* v
* t
* e

Pharmaceutical and biotechnology industry in the United Kingdom

* Manufacturing in the United Kingdom
* Economy of the United Kingdom

Companies|

| Current|

* AAH Pharmaceuticals
* Alliance Boots
* Astex
* AstraZeneca (MedImmune)
* BTG
* Cyclacel
* Dechra Pharmaceuticals
* GE HealthCare
* Genus
* GSK
* Hikma Pharmaceuticals
* Indivior
* IXICO
* MacFarlan Smith
* Mundipharma
* Norbrook Group
* Oxford Biomedica
* Pfizer UK
* Proximagen
* Silence Therapeutics
* TBS GB
* Vectura
* Vernalis
* ViiV Healthcare

|

Defunct|

* Allen & Hanburys
* Amersham
* Beecham Group
* Cambridge Antibody Technology
* Celltech
* Chiroscience
* The Distillers Company
* Fisons
* Glaxo Wellcome
* ICI
* Phytopharm
* Reliant Pharmaceuticals
* Renovo
* Shire
* Unipath
* Zeneca

Government and
regulatory bodies|

* Commission on Human Medicines
* Department of Health
* European Directorate for the Quality of Medicines & HealthCare
* Medicines and Healthcare products Regulatory Agency
* National Collaborating Centre for Mental Health
* Pharmaceutical Price Regulation Scheme
* Pharmaceutical Society of Northern Ireland
* General Pharmaceutical Council
* Scottish Medicines Consortium
* Veterinary Medicines Directorate

Industry and
professional bodies|

* Association of the British Pharmaceutical Industry
* Chemical Industries Association
* European Federation of Biotechnology
* European Federation of Pharmaceutical Industries and Associations
* Faculty of Pharmaceutical Medicine
* Pharmacists' Defence Association
* Royal Pharmaceutical Society of Great Britain
* Worshipful Society of Apothecaries

Books and journals|

* Bandolier
* Bad Pharma (2012)
* British National Formulary
* British National Formulary for Children
* British Pharmaceutical Codex
* Journal of Pharmacy and Pharmacology
* Monthly Index of Medical Specialities
* Side Effects (2008)
* The Pharmaceutical Journal

Other|

* British Approved Name
* British Pharmacopoeia
* DrugScope
* European and Developing Countries Clinical Trials Partnership
* European Pharmacopoeia
* List of world's largest pharmaceutical companies
* Pharmaceutical Services Negotiating Committee
* Wellcome Trust

* category

*[v]: View this template
*[t]: Discuss this template
*[e]: Edit this template